ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 3030

Evidence of Inflammasome Activation in the Peripheral Blood and Salivary Gland Tissues of Primary Sjögren’s Syndrome Patients: Correlation with Clinical Indices of Severe Disease and Lymphoma Development

Aglaia G Vakrakou1,2, Sorina Boiu3,4 and Menelaos N Manoussakis1,5, 1Hellenic Pasteur Institute, Athens, Greece., Hellenic Pasteur Institute, Athens, Greece, Athens, Greece, 2Department of Pathophysiology, Department of Pathophysiology, School of Medicine, University of Athens, Greece, Athens, Greece, 3Department of Pathophysiology, School of Medicine, University of Athens, Greece, Athens, Greece, 4Hellenic Pasteur Institute, Athens, Greece, Athens, Greece, 5Department of Pathophysiology, School of Medicine, University of Athens, Greece, Department of Pathophysiology, School of Medicine, University of Athens, Greece, Athens, Greece

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: Sjogren's syndrome and inflammasome activation

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Sjögren's Syndrome I: Clinical Insights

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:  Inflammasomes are intracellular multiprotein complexes that sense pathogenic microorganisms, as well as danger signals released following tissue injury. Such activation of inflammasome leads to the upregulation of various inflammasome-related molecules and the release of pro-inflammatory cytokines, namely interleukin-1β (IL-1β) and interleukin-18 (IL-18). In this study, we sought to investigate the inflammasome activation status in the peripheral blood and the salivary gland (SG) tissues of SS patients and its relationship with indices of disease activity and severity.

Methods:  PBMC mRNA expression of inflammasome-related molecules NLRP3, AIM2, ASC, pro-caspase-1, IL-1β, IL-18 as well as the interferon type I signature genes MX1 and IF44L was evaluated by RT-PCR. Serum expression of inflammasome proteins ASC, IL-1β and IL-18 was evaluated by ELISA. SG biopsies were examined for the presence of inflammasome-related proteins by confocal microscopy.

Results: Compared to healthy controls (n=20), SS patients exhibited significantly higher serum levels of ASC (n=56; p=0.002), IL-1β (n=37; p=0.003) and IL-18 (n=33; p<0.0001). The serum levels of ASC protein were significantly higher in SS patients at high risk for lymphoma development (SS-type I; n=17) and in SS patients with lymphoma (n=28), compared to SS patients with low risk for lymphoma development (SS-type II; n=11, for p=0.030 and p=0.004, respectively). In SS patients, the serum levels of ASC and IL-18 correlated positively with the total cumulative ESSDAI score values (p=0.005 and p=0.006, respectively), whereas ASC levels correlated with the presence of C4 hypocomplementemia (p=0.002), rheumatoid factor (p=0.02) and purpura (p=0.02). In addition, compared to healthy controls (n=16), the PBMC of SS patients expressed significantly higher levels of ASC, NLRP3, IL-1β, IL-18 and pro-caspase-1 transcripts (n=39, p<0.05). The calculation of the NLRP3-inflammasome score in PBMC indicated an optimal discrimination between SS clinical subgroups (AUC=0.915) and positively correlated with interferon type I expression (Spearman r=0.443, p= 0.0006, n=37). In the SG tissues of SS patients, CD68+ macrophages and epithelial cells manifested high expression of ASC protein that was localized in perinuclear aggregates (specks), suggesting inflammasome activation. Co-localization experiments showed significantly increased ASC expression in CD68+ macrophages in SS (p<0.0001), compared with non-SS control patients.

Conclusion:  Our findings indicate that SS patients manifest evidence of inflammasome activation in both peripheral blood and the SG tissues. Several indices of inflammasome activation correlated with the presence of severe disease, as well as lymphoma development and may constitute valuable clinical biomarkers for these patients.


Disclosure: A. G. Vakrakou, None; S. Boiu, None; M. N. Manoussakis, None.

To cite this abstract in AMA style:

Vakrakou AG, Boiu S, Manoussakis MN. Evidence of Inflammasome Activation in the Peripheral Blood and Salivary Gland Tissues of Primary Sjögren’s Syndrome Patients: Correlation with Clinical Indices of Severe Disease and Lymphoma Development [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/evidence-of-inflammasome-activation-in-the-peripheral-blood-and-salivary-gland-tissues-of-primary-sjogrens-syndrome-patients-correlation-with-clinical-indices-of-severe-disease-and-lymphoma/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2016

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evidence-of-inflammasome-activation-in-the-peripheral-blood-and-salivary-gland-tissues-of-primary-sjogrens-syndrome-patients-correlation-with-clinical-indices-of-severe-disease-and-lymphoma/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology